Mostrar el registro sencillo del ítem

Development of New Serum Biomarkers for Early Lymphedema Detection

dc.contributor.authorHerrada A.A.
dc.contributor.authorMejías C.
dc.contributor.authorLazo-Amador R.
dc.contributor.authorOlate-Briones A.
dc.contributor.authorLara D.
dc.contributor.authorEscobedo N.
dc.date.accessioned2020-09-02T22:20:31Z
dc.date.available2020-09-02T22:20:31Z
dc.date.issued2020
dc.identifier10.1089/lrb.2019.0008
dc.identifier.citation18, 2, 136-145
dc.identifier.issn15396851
dc.identifier.urihttps://hdl.handle.net/20.500.12728/4904
dc.descriptionBackground: Early lymphedema detection may reduce the symptoms and improve clinical outcomes. However, the lack of reliable serum biomarkers capable of predicting lymphedema development is a current medical problem. In this study, we investigated if serum levels of hyaluronic acid (HA) and leukotriene B4 (LTB4), two molecules involved in lymphedema development, may work as predictors of this condition. Methods and Results: A mouse model of acquired lymphedema was generated through ablation of tail dermal lymphatic network. Tail diameter was measured daily, and HA and LTB4 serum levels were analyzed before and during the development of lymphedema. We found increased serum levels of HA and reduced levels of LTB4 at early days before the appearance of lymphedema signs. Similar results were observed in the lymphedema tissue. Increased local and systemic inflammation was also detected at early time points. Moreover, the ratio LTB4/HA arises as the strongest predictor for lymphedema development. In fact, we found an inverse correlation in our model, where reduced LTB4/HA levels showed increased lymphedema signs. Conclusions: These findings suggest that serum ratio of LTB4/HA may be a useful biomarker to predict acquired lymphedema development, with potential to be used in clinical conditions such as breast cancer patients. © Copyright 2020, Mary Ann Liebert, Inc., publishers 2020.
dc.language.isoen
dc.publisherMary Ann Liebert Inc.
dc.subjectacquired lymphedema
dc.subjectbiological markers
dc.subjectmouse model
dc.subjectserum
dc.subjectbiological marker
dc.subjecthyaluronic acid
dc.subjectleukotriene B4
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectArticle
dc.subjectblood level
dc.subjectbreast cancer
dc.subjectcontrolled study
dc.subjectearly diagnosis
dc.subjectenzyme linked immunosorbent assay
dc.subjecthistology
dc.subjecthyaluronic acid blood level
dc.subjectinfant
dc.subjectinflammation
dc.subjectleukotriene B4 blood level
dc.subjectlymphedema
dc.subjectmouse
dc.subjectnonhuman
dc.subjectprediction
dc.subjectpriority journal
dc.subjectreal time polymerase chain reaction
dc.subjecttail
dc.titleDevelopment of New Serum Biomarkers for Early Lymphedema Detection
dc.typeArticle


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-85083914397.pdf
Tamaño:
2.905Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem